What question did this study set out to answer?

To evaluate clinical features and prognosis in autoimmune encephalitis associated with antibodies against surface antigens and to identify influencing factors for relapse.

March 10, 2026Open Access

Clinical features, prognosis, and influencing factors of relapse in autoimmune encephalitis associated with antibodies against cell surface antigens: a single-center retrospective study

Q: What does this research mean for the field?

Hospital stay duration, CRP, and CAR are independent biomarkers that predict poor prognosis in patients with autoimmune encephalitis associated with antibodies against cell surface antigens. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Puntos clave

To evaluate clinical features and prognosis in autoimmune encephalitis associated with antibodies against surface antigens and to identify influencing factors for relapse.
Conducted a single-center retrospective analysis of autoimmune encephalitis patients
Analyzed demographic, clinical, laboratory, and imaging data
Identified biomarkers like CRP and CAR for prognosis assessment
Autoimmune encephalitis subtypes show significant differences in clinical characteristics
Hospital stay duration, CRP, and CAR emerge as independent predictors of poor prognosis
Early identification of relapse potential is vital for improving outcomes

Resumen

AEASA subtypes differ significantly in demographic characteristics, clinical manifestations, laboratory results, and imaging findings, forming distinct disease spectra. Hospital stay duration, CRP, and CAR are robust, independent biomarkers for predicting poor prognosis in AEASA patients, providing important guidance for clinical risk stratification and treatment decisions. Early identification and intervention for high-risk patients with relapse potential are crucial for improving long-term prognosis.

Me gusta

Guardar

Ver artículo completo